Eris Lifesciences Peer Comparison

NSE: ERIS | BSE: 540596

₹1,324.30

₹2.60 (0.20%)

As on 07-Sep-2026IST

Market cap

₹18,338 Cr

Revenue (TTM)

₹3,230 Cr

P/E Ratio

28.5

P/B Ratio

4.5

Div. Yield

0 %

Edit

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Market cap (₹ Cr)	18,338	21,296	21,044	18,318	17,072
Revenue (₹ Cr)	3,230	2,287	2,570	1,682	2,432
Net Profit (₹ Cr)	666.92	678.07	735.15	273.51	169.62
Net Margin (%)	20.60	28.10	26.88	16.19	6.90
RoE (%)	18.75	19.73	19.16	11.15	20.76
Price to Earnings	28.48	32.01	28.63	61.61	100.65
Price-To-Book	4.55	5.80	4.77	6.82	18.88

Income Statement (₹ Cr)

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Operating Revenue	3,229.67	2,287.33	2,569.77	1,682.47	2,432.06
Total Income	3,237.12	2,413.29	2,735.39	1,689.83	2,458.54
Total Expenditure	2,090.06	1,490.75	1,628.14	1,203.91	2,202.20
EBITDA	1,139.61	796.58	941.63	478.55	229.86
Depreciation	281.06	78.10	57.58	126.01	17.24
EBIT	858.55	718.48	884.05	352.55	212.62
Interest	190.64	0.88	7.69	52.11	5.72
Other Income	7.45	125.96	165.62	7.37	26.48
Exceptional Items	-17.24	0.00	-49.16	12.16	-5.13
Profit before Tax	658.12	843.56	992.82	319.96	228.25
Provision for Tax	-8.80	165.49	257.67	46.45	58.63
Profit after Tax	666.92	678.07	735.15	273.51	169.62

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Shareholder's Funds	3,902.67	3,586.42	4,202.90	2,591.20	872.79
Minority Interest	-21.81	-12.71	0.00	0.00	0.00
Non-Current Liabilities	1,392.75	28.74	91.50	266.35	134.50
Current Liabilities	2,077.10	385.94	627.48	848.06	981.81
Total Liabilities	7,246.72	4,037.51	4,921.88	3,705.61	2,414.58

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Non-Current Assets	5,617.77	1,291.22	770.28	2,525.44	42.47
Current Assets	1,539.85	2,585.66	3,803.22	1,109.77	1,739.93
Total Assets	7,246.72	4,037.51	4,921.88	3,705.61	2,414.58
Total Debt*	2,309.68	0.57	2.50	657.97	0.00
Net Current Assets	-537.25	2,199.72	3,175.74	261.71	758.12
Contingent Liabilities	51.57	17.53	370.49	160.01	121.23

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Cash From Operating Activities	537.99	523.24	967.57	342.18	-15.14
Cash Flow from Investing Activities	-369.46	-582.30	-561.67	-325.92	18.69
Cash from Financing Activities	-313.53	-46.46	-798.31	13.62	-91.97
Net Cash Inflow / Outflow	-145.00	-105.52	-392.41	29.88	-88.42

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
ROCE (%)	14.47	24.97	23.39	11.43	31.24
ROE (%)	18.75	19.73	19.16	11.15	20.76
ROA (%)	9.26	18.69	14.95	7.80	9.67
EBIT Margin (%)	26.58	31.41	34.40	20.95	8.74
Net Margin (%)	20.60	28.10	26.88	16.19	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Revenue Growth (%)	9.59	15.01	10.69	27.91	31.10
EBIT Growth (%)	16.84	18.45	24.14	58.32	-12.99
Net Profit Growth (%)	62.68	19.61	-9.09	149.56	-7.49
EPS Growth (%)	67.41	17.73	14.40	-3.57	-18.33
Book Value Growth (%)	36.71	26.75	-0.34	9.67	13.51

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Price / Earnings	27.77	32.15	27.17	65.00	99.09
Price / Book Value	4.54	5.82	4.76	6.78	19.02
Dividend Yield (%)	0.00	0.28	1.64	0.06	0.52
EV/EBITDA	18.05	25.59	18.96	39.35	72.85
Market Cap (₹ Cr)	17,980.08	11,439.22	21,592.90	6,819.66	19,398.64

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Debt to Equity	0.24	0.00	0.00	0.07	0.00
Short term debt to equity ratio	0.12	0.00	0.00	0.16	--
Current Ratio	0.74	6.70	6.06	1.31	1.77
Quick Ratio	0.53	5.59	5.31	0.88	0.73
Interest Coverage	4.45	959.59	130.11	7.14	40.90

	Eris Lifesciences	Caplin Point Lab	Pfizer	Shilpa Medicare	Astrazeneca Pharma
Debtors to sales (%)	21.07	36.10	7.07	30.84	8.79
Asset Turnover	0.45	0.63	0.52	0.48	1.39
Receivable days	63.88	121.68	26.06	113.81	31.88
Inventory Days	43.27	63.83	65.95	84.76	126.03
Payable days	151.85	108.28	81.01	101.94	163.79
Cash Conversion Cycle	-44.70	77.23	11.00	96.62	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.